Bachem vs PolyPeptide vs AmbioPharm: CDMOs

Pharmaceutical and biotech firms that need peptides made to clinical or commercial standards usually go to a contract development and manufacturing organization (CDMO). Three names come up again and again: Bachem, PolyPeptide Group, and AmbioPharm. Each has a different ownership structure and geographic footprint. All three publicly describe capabilities that run from research-scale synthesis through commercial API supply under current Good Manufacturing Practice (cGMP) conditions.

Company Profiles at a Glance

Bachem (headquartered in Bubendorf, Switzerland) is the oldest of the three. It is publicly traded on the SIX Swiss Exchange (ticker BANB). The company states it was founded in 1971 and has manufactured peptides under GMP guidelines since the late 1970s, and it describes itself as focused on peptide and oligonucleotide development and manufacturing. Per Bachem's own history materials, its international expansion began with a US subsidiary in 1987, followed by a 1996 acquisition that added US, German, and UK operations.

PolyPeptide Group (headquartered in Baar, in the canton of Zug, Switzerland) is publicly listed on the SIX Swiss Exchange under the ticker PPGN. The company describes a manufacturing network spanning Sweden, Belgium, France, the United States, and India, and positions itself as a focused peptide CDMO. Its public history traces commercial peptide manufacturing in Malmö, Sweden back to 1952 within Ferring Pharmaceuticals, with the PolyPeptide Group itself formed in 1996. PolyPeptide states that its facilities operate under cGMP frameworks recognized by the FDA, EMA, and other regulatory agencies.

AmbioPharm (headquartered in North Augusta, South Carolina, USA) describes its focus as custom peptide synthesis, at scales from milligrams up to large commercial quantities. According to the May 2026 acquisition announcement (see below), AmbioPharm was founded in 2005 and operates two manufacturing sites, one in South Carolina and one in Shanghai, China, with roughly 400 employees. AmbioPharm's public materials reference FDA-inspected facilities and cGMP manufacturing for both clinical and commercial supply.

Side-by-Side Comparison

Every figure above comes from each company's publicly available materials and reputable trade-press reporting. Verify it directly with the company before relying on it for any procurement or regulatory purpose.

Recent Ownership Developments (2026)

Two of these three companies saw major corporate activity in 2026.

• AmbioPharm. On May 27, 2026, CordenPharma announced an agreement to acquire AmbioPharm, describing it as a US-headquartered peptide API CDMO with sites in South Carolina and Shanghai. The companies stated the transaction remained subject to customary closing conditions and that financial terms were not disclosed (PR Newswire / CordenPharma announcement).
• PolyPeptide Group. In April 2026, PolyPeptide confirmed that its board, together with majority shareholder Draupnir Holding B.V., was conducting an early-stage review of strategic options. This followed trade-press reports (Bloomberg) of takeover interest from private-equity firms. The company stated the review was at an early stage with no assurance of any transaction (PolyPeptide statement). As of this writing, PolyPeptide remained listed on the SIX Swiss Exchange.

Both situations were still developing as of mid-2026. Check each company's current investor communications for the latest status.

What "cGMP" Means in This Context

cGMP (current Good Manufacturing Practice) is the regulatory standard enforced by agencies such as the FDA and EMA for the manufacture of pharmaceutical-grade materials. A facility described as cGMP-compliant has, in principle, been designed and operated to minimize contamination risk, maintain batch traceability, and pass regulatory inspection. For peptide CDMOs, that usually means documentation of raw materials, in-process testing, and release testing for identity, purity, and potency.

cGMP status is process- and facility-specific. A CDMO may run some production lines under cGMP and not others. Buyers doing supplier qualification are generally expected to request certificates of analysis (COAs), audit reports, and Drug Master File (DMF) references directly from the manufacturer.

Regulatory and Quality Credentials

All three companies publicly reference FDA and EMA compliance across at least some of their sites, and all describe Drug Master File (DMF) or equivalent submission capability to support client regulatory filings. Bachem and PolyPeptide both reference European Pharmacopoeia (Ph. Eur.) and United States Pharmacopeia (USP) standards in their public documentation. AmbioPharm states its facilities have been inspected multiple times by the FDA and other regulatory bodies.

None of this guarantees quality for any specific batch or client project. The third-party independent batch-testing services common in the research-peptide market do not typically apply at the pharma CDMO level, where the regulatory framework itself mandates batch documentation. Procurement teams working at this level should conduct formal audits and request regulatory correspondence directly. Materials produced for the research-peptide market are sold for research use only and are not approved for human consumption.

Sources

• bachem.com — company history and locations
• polypeptide.com — company history, locations, and investor information
• ambiopharm.com — manufacturing facilities and news
• CordenPharma / PR Newswire — May 2026 AmbioPharm acquisition announcement
• fda.gov — cGMP regulations and guidance
• ema.europa.eu — EMA GMP guidelines
• usp.org — USP peptide standards